Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 7/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23064386 | 1.00 | TRPA1 (0.51) | TRPA1MEN1KMT2ATRPV1KCNH2 | |
| SCHEMBL25844259 | 0.83 | TRPA1 (0.48) | TRPA1TRPV1 | |
| SCHEMBL25844260 | 0.82 | RBP4 (0.48) | TRPA1TRPV1KCNH2TRPM8KDM4E | |
| SCHEMBL23064252 | 0.81 | TRPA1 (0.52) | TRPA1TRPV1HSD17B10 | |
| SCHEMBL30633886 | 0.81 | TRPA1 (0.52) | TRPA1TRPV1HSD17B10 | |
| SCHEMBL23283042 | 0.81 | TRPA1 (0.53) | TRPA1MEN1KMT2ATRPV1KCNH2 | |
| SCHEMBL26669421 | 0.81 | MEN1 (0.74) | TRPA1MEN1KMT2ATRPV1KCNH2 | |
| SCHEMBL30633892 | 0.79 | AKR1C3 (0.49) | MEN1KMT2AKDM4ESMN1; SMN2HSD17B10 | |
| SCHEMBL31050090 | 0.79 | AKR1C3 (0.49) | MEN1KMT2AKDM4ESMN1; SMN2HSD17B10 | |
| SCHEMBL23064314 | 0.79 | AKR1C3 (0.49) | MEN1KMT2AKDM4ESMN1; SMN2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250170116-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND/OR TREATING RENAL DISEASE | OSAKA UNIVERSITY (JP) | 2025-05-29 | — | — | US | disclosed |
| US-20250073229-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND/OR TREATING HEART FAILURE | SHINSHU UNIVERSITY (JP) | 2025-03-06 | — | — | US | disclosed |
| EP-4487848-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND/OR TREATING RENAL DISEASE | OSAKA UNIVERSITY (JP) | 2025-01-08 | — | — | EP | disclosed |
| EP-4461296-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND/OR TREATING HEART FAILURE | Osaka University (JP) | 2024-11-13 | — | — | EP | disclosed |
| CN-118678955-A | Pharmaceutical composition for preventing and/or treating heart failure | 国立大学法人大阪大学 | 2024-09-20 | — | — | CN | disclosed |
| US-20240307375-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND/OR TREATING KIDNEY INJURY, AND AUTOPHAGY ACTIVATOR | KYOTO UNIVERSITY (JP) | 2024-09-19 | — | — | US | disclosed |
| CN-112204017-B | Benzisoxazole compounds | 国立大学法人大阪大学 | 2024-08-20 | — | — | CN | disclosed |
| EP-4364739-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND/OR TREATING KIDNEY INJURY, AND AUTOPHAGY ACTIVATOR | OSAKA UNIVERSITY (JP) | 2024-05-08 | — | — | EP | disclosed |
| US-11976062-B2 | Benzisoxazole compound | OSAKA UNIVERSITY (JP) | 2024-05-07 | — | — | US | disclosed |
| EP-3789383-B9 | INHIBITORS OF THE TRPC3 OR TRPC6 CHANNEL | UNIV OSAKA (JP) | 2024-02-28 | — | — | EP | disclosed |
| CN-117580577-A | Pharmaceutical composition for preventing and/or treating kidney injury and autophagy activator | 国立大学法人大阪大学 | 2024-02-20 | — | — | CN | disclosed |
| EP-3789383-B1 | INHIBITORS OF THE TRPC3 OR TRPC6 CHANNEL | UNIV OSAKA (JP) | 2023-11-29 | — | — | EP | disclosed |
| WO-2023163203-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND/OR TREATING RENAL DISEASE | 国立大学法人大阪大学 | 2023-08-31 | — | — | WO | disclosed |
| WO-2023132208-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND/OR TREATING HEART FAILURE | 国立大学法人大阪大学 | 2023-07-13 | — | — | WO | disclosed |
| US-20230114195-A1 | BENZISOXAZOLE COMPOUND | KYOTO UNIVERSITY (JP) | 2023-04-13 | — | — | US | disclosed |
| US-11548882-B2 | Benzisoxazole compound | OSAKA UNIVERSITY (JP) | 2023-01-10 | — | — | US | disclosed |
| WO-2023276828-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND/OR TREATING KIDNEY INJURY, AND AUTOPHAGY ACTIVATOR | 国立大学法人大阪大学 | 2023-01-05 | — | — | WO | disclosed |
| US-20210238171-A1 | BENZISOXAZOLE COMPOUND | INTER-UNIVERSITY RESEARCH INSTITUTE CORPORATION NATIONAL INSTITUTES OF NATURAL SCIENCES (JP) | 2021-08-05 | — | — | US | disclosed |
| EP-3789383-A1 | BENZISOXAZOLE COMPOUND | Osaka University (JP) | 2021-03-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238171-A1 | BENZISOXAZOLE COMPOUND | CBR1, CYP2S1, CYP2E1 | TRPA1 1697/4885MEN1 3672/4885KMT2A 2741/4885 |
| US-20240307375-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND/OR TREATING KIDNEY INJURY, AND AUTOPHAGY ACTIVATOR | ATG7, BECN1, SQSTM1 | TRPA1 2507/4885MEN1 4619/4885KMT2A 3164/4885 |
| US-11976062-B2 | Benzisoxazole compound | CBR1, CYP2S1, CYP2E1 | TRPA1 1638/4885MEN1 3694/4885KMT2A 2707/4885 |
| US-20250170116-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND/OR TREATING RENAL DISEASE | REN, ATP6V1B1, CYP2S1 | TRPA1 2551/4885MEN1 2906/4885KMT2A 4345/4885 |
| US-11548882-B2 | Benzisoxazole compound | CBR1, CYP2S1, CYP2E1 | TRPA1 1697/4885MEN1 3672/4885KMT2A 2741/4885 |
| US-20230114195-A1 | BENZISOXAZOLE COMPOUND | CBR1, CYP2S1, CYP2E1 | TRPA1 1702/4885MEN1 3692/4885KMT2A 2621/4885 |
| US-20250073229-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND/OR TREATING HEART FAILURE | CBR1, CYP2S1, CYP2F1 | TRPA1 2077/4885MEN1 3861/4885KMT2A 4014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.